Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hugo Geerts

Showing results (61-70 of 71) with videos related to

Pageof 8
Sort By:
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|May 31, 2016
Big data to smart data in Alzheimer's disease: The brain health modeling initiative to foster actionable knowledgeHugo Geerts, Penny A Dacks, Viswanath Devanarayan, et al.
Therapie|June 23, 2005
[Pharmacology of Alzheimer's disease: where do we go from here?]François Sellal, André Nieoullon, Géraldine Michel, et al.
Dementia and Geriatric Cognitive Disorders|March 16, 2005
Pharmacology of Alzheimer's disease: appraisal and prospectsFrançois Sellal, André Nieoullon, Géraldine Michel, et al.
ALTEX|April 11, 2022
The future of Parkinson's disease research: A new paradigm of human-specific investigation is necessary… and possibleManuela Cassotta, Hugo Geerts, Lise Harbom, et al.
Proteomics|January 15, 2002
Differential expression of brain proteins in glycogen synthase kinase-3 transgenic mice: a proteomics point of viewKelly Tilleman, Ilse Stevens, Kurt Spittaels, et al.
Neurobiology of Disease|December 31, 2002
In vitro studies of Flemish, Dutch, and wild-type beta-amyloid provide evidence for two-staged neurotoxicitySamir Kumar-Singh, Ann Julliams, Rony Nuydens, et al.
CPT: Pharmacometrics & Systems Pharmacology|January 12, 2023
A combined physiologically-based pharmacokinetic and quantitative systems pharmacology model for modeling amyloid aggregation in Alzheimer's diseaseHugo Geerts, Mike Walker, Rachel Rose, et al.
CPT: Pharmacometrics & Systems Pharmacology|November 2, 2019
Quantitative Systems Pharmacology for Neuroscience Drug Discovery and Development: Current Status, Opportunities, and ChallengesHugo Geerts, John Wikswo, Piet H van der Graaf, et al.
Clinical Pharmacology and Therapeutics|December 5, 2024
Quantitative Systems Pharmacology-Based Digital Twins Approach Supplements Clinical Trial Data for Enzyme Replacement Therapies in Pompe DiseaseChanchala Kaddi, Mengdi Tao, Silke Bergeler, et al.
Clinical Pharmacology and Therapeutics|January 20, 2020
Challenges in Alzheimer's Disease Drug Discovery and Development: The Role of Modeling, Simulation, and Open DataDaniela J Conrado, Sridhar Duvvuri, Hugo Geerts, et al.
Pageof 8

Showing results (61-70 of 71) with videos related to

Sort By:
Pageof 8
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|May 31, 2016
Big data to smart data in Alzheimer's disease: The brain health modeling initiative to foster actionable knowledgeHugo Geerts, Penny A Dacks, Viswanath Devanarayan, et al.
Therapie|June 23, 2005
[Pharmacology of Alzheimer's disease: where do we go from here?]François Sellal, André Nieoullon, Géraldine Michel, et al.
Dementia and Geriatric Cognitive Disorders|March 16, 2005
Pharmacology of Alzheimer's disease: appraisal and prospectsFrançois Sellal, André Nieoullon, Géraldine Michel, et al.
ALTEX|April 11, 2022
The future of Parkinson's disease research: A new paradigm of human-specific investigation is necessary… and possibleManuela Cassotta, Hugo Geerts, Lise Harbom, et al.
Proteomics|January 15, 2002
Differential expression of brain proteins in glycogen synthase kinase-3 transgenic mice: a proteomics point of viewKelly Tilleman, Ilse Stevens, Kurt Spittaels, et al.
Neurobiology of Disease|December 31, 2002
In vitro studies of Flemish, Dutch, and wild-type beta-amyloid provide evidence for two-staged neurotoxicitySamir Kumar-Singh, Ann Julliams, Rony Nuydens, et al.
CPT: Pharmacometrics & Systems Pharmacology|January 12, 2023
A combined physiologically-based pharmacokinetic and quantitative systems pharmacology model for modeling amyloid aggregation in Alzheimer's diseaseHugo Geerts, Mike Walker, Rachel Rose, et al.
CPT: Pharmacometrics & Systems Pharmacology|November 2, 2019
Quantitative Systems Pharmacology for Neuroscience Drug Discovery and Development: Current Status, Opportunities, and ChallengesHugo Geerts, John Wikswo, Piet H van der Graaf, et al.
Clinical Pharmacology and Therapeutics|December 5, 2024
Quantitative Systems Pharmacology-Based Digital Twins Approach Supplements Clinical Trial Data for Enzyme Replacement Therapies in Pompe DiseaseChanchala Kaddi, Mengdi Tao, Silke Bergeler, et al.
Clinical Pharmacology and Therapeutics|January 20, 2020
Challenges in Alzheimer's Disease Drug Discovery and Development: The Role of Modeling, Simulation, and Open DataDaniela J Conrado, Sridhar Duvvuri, Hugo Geerts, et al.
Pageof 8